Related references
Note: Only part of the references are listed.Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Rong Deng et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics
Jing Yu et al.
AAPS JOURNAL (2011)
Bioanalytical Approaches to Quantify Total and Free Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
Jean W. Lee et al.
AAPS JOURNAL (2011)
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models
Philip J. Lowe et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
Alison M. Betts et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody
Wendy S. Putnam et al.
AAPS JOURNAL (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
Paul M. Beer et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
E Ädelroth et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
Share Paper
